Majority of results from late-stage trials of failed drugs not published

Over the course of a decade, 54% of drugs and biologics in late-stage trials failed due to poor efficacy or safety concerns, according to findings published in JAMA Internal Medicine.Researchers published the trial results in peer-reviewed journals for 40% of these drugs, Thomas J. Hwang, AB, from the Program on Regulation, Therapeutics, and Law (PORTAL) at Brigham and Women's Hospital and Harvard Medical School, and colleagues wrote.